1. Cunningham MJ. Update on thalassemia: clinical care and complications. Pediatr Clin North Am. 2008; 55(2):447-60, ix. PMID: 18381095 DOI: 10.1016/j.pcl.2008.02.002
2. Miri-Aliabad G, Fadaee M, Khajeh A, Naderi M. Marital status and fertility in adult Iranian patients with β-Thalassemia Major. Indian J Hematol Blood Transfus. 2016;32:110-113. PMID: 26855517 DOI: 10.1007/s12288-015-0510-9
3. Miri-Aliabad G, Rezaeifar A, Salarzaei M. Comparison of Immunoglobulins Status In Splenectomized And Non-Splenectomized Patients With Major Beta-Thalassemia. J Pediatr Rev. 2022; 10 (2):161-166. DOI: 10.32598/jpr.10.2.951.2
4. Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021; 384(8):727-743. PMID: 33626255 DOI: 10.1056/NEJMra2021838
5. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-3488. PMID: 21813448 DOI: 10.1182/blood-2010-08-300335
6. Sabath DE. Molecular diagnosis of thalassemias and hemoglobinopathies: an ACLPS critical review. Am J clin pathol. 2017; 148(1):6-15. PMID: 28605432 DOI: 10.1093/ajcp/aqx047
7. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert Rev Hematol. 2010; 3: 103-117. PMID: 21082937 DOI: 10.1586/ehm.09.74
8. Miri-Aliabad G, Asgarzadeh L, Dorgalaleh A, Bahraini M. Prevalence of Acute Complications of Transfusion in Children with β-thalassemia Major in Southeast Iran: A Prospective Study. J Kerman Univ Med Sci. 2023;30(4):229-32. DOI:10.34172/jkmu.2023.38
9. Miri-Aliabad G, Tabatabaei SM, Vaezi Z, Amini A, Asgarzadeh L. Causes of birth of more than one thalassemia major patient in families in south-east of Iran: lessons for prevention programs. Health Scope. 2021;10(3): e116634. DOI:10.5812/jhealthscope.116634
10. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010; 5:1-15. PMID: 20492708 DOI: 10.1186/1750-1172-5-11
11. Tari K, Valizadeh Ardalan P, Abbaszadehdibavar M, Atashi A, Jalili A, Gheidishahran M. Thalassemia an update: molecular basis, clinical features and treatment. Int J Biomed Public Health. 2018;1(1):48-58. Link
12. Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin. Adv Nutr. 2017; 8(1), 126–136. PMID: 28096133 DOI: 10.3945/an.116.013961
13. Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior. Caspian J Intern Med. 2017; 8(3):159-164. PMID: 28932366 DOI: 10.22088/cjim.8.3.159
14. Sarnaik SA. Thalassemia and related hemoglobinopathies. Indian J Pediatr. 2005; 72(4):319-324. PMID: 15876761 DOI: 10.1007/BF02724015
15. Origa R. β-Thalassemia. Genet Med. 2017; 19(6):609-619.
16. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. British J Haematol. 2011; 152(5): 512–523. PMID: 21250971 DOI: 10.1111/j.1365-2141.2010.08486.x
17. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory diagnosis of thalassemia. Front Mol Biosci. 2020; 7:74. PMID: 32671092 DOI: 10.3389/fmolb.2020.00074
18. Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016; 38:32-40. PMID: 27183541 DOI: 10.1111/ijlh.12527
19. Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014; 31(7):583-596. PMID: 25247665 DOI: 10.3109/08880018.2014.937884
20. Lal A, Wong T, Keel S, Pagano M, Chung J, Kamdar A, et al. The transfusion management of beta thalassemia in the United States. Transfusion. 2021; 61(10):3027-3039. PMID: 34453453 DOI: 10.1111/trf.16640
21. Borgna-Pignatti C, Marsella M. Iron Chelation in Thalassemia Major. Clin Ther. 2015; 37(12):2866-2877. PMID: 26519233 DOI: 10.1016/j.clinthera.2015.10.001
22. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012; 120(18):3657-3669. PMID: 22919029 DOI: 10.1182/blood-2012-05-370098
23. Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, et al. Iron Chelators in Treatment of Iron Overload. J Toxicol. 2022; 2022(1):4911205. PMID: 35571382 DOI: 10.1155/2022/4911205
24. Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Iron overload disorders. Hepatol Commun. 2022; 6(8):1842-1854. PMID: 35699322 DOI: 10.1002/hep4.2012
25. Tartaglione I, Origa R, Kattamis A, Pfeilstöcker M, Gunes S, Crowe S, et al. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Exp Hematol Oncol. 2020; 9:20. PMID: 32793403 DOI: 10.1186/s40164-020-00174-2
26. Naderi M, Miri Aliabad G, Soleimani G, Soleimanzadeh Mousavi H, Yaghoubi S. Comparison of quality of life in thalassemia major patients with injectable and oral iron depletion. Int J Pediatr. 2021; 9 (11):14747-14755. DOI:10.22038/ijp.2021.54193.4285
27. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010; 8(10):2152-2158. PMID: 20546125 DOI: 10.1111/j.1538-7836.2010. 03940.x
28. Saliba AN, Musallam KM, Taher AT. How I treat non-transfusion-dependent β-thalassemia. Blood. 2023; 142(11):949-960. PMID: 34889443 DOI:10.1182/hematology.2021000313
29. Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood adv. 2021; 5(1):326-333. PMID: 33570654 DOI:10.1182/bloodadvances.2020002725
30. Langer AL, Esrick EB. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):600-606.
31. Breda L, Kleinert DA, Casu C, Casula L, Cartegni L, Fibach E, et al. A preclinical approach for gene therapy of beta-thalassemia. Ann N Y Acad Sci. 2010; 1202:134-140. PMID: 20712784 DOI: 10.1111/j.1749-6632.2010.05594.x
32. de Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for beta-thalassemia major. Biomed J. 2016; 39(1):24-38. PMID: 27105596 DOI: 10.1016/j.bj.2015.10.001
33. Vermylen C. What is new in iron overload? Eur J Pediatr. 2008; 167: 377-381. PMID: 17899187 DOI: 10.1007/s00431-007-0604-y
34. Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010; 89(6): 585-589. PMID: 20016898 DOI: 10.1007/s00277-009-0879-3
35. Riaz M, Abbas M, Rasool G, Baig IS, Mahmood Z, Munir N, et al. Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review. Int J Immunopathol Pharmacol. 2022; 36:3946320221096909. PMID: 35452334 DOI: 10.1177/03946320221096909
36. Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E, et al. Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited. Acta Biomed. 2022; 93(5): e2022305. PMID: 36300213 DOI: 10.23750/abm.v93i5.13668
37. Miri-Aliabad G, Nakhaie Moghadam M, Naderi M, Saravani M, Saravani R, Sargazi S, et al. Adrenal Insufficiency in Patients with Beta-Thalassemia Major in the Southeast of Iran. Int J Hematol Oncol Stem Cell Res. 2022; 16(3):174-176. PMID: 36694703 DOI: 10.18502/ijhoscr.v16i3.10140
38. Yousefian S, Mirialiabad G, Saleh R, Khedmati M. Association of Body mass index and serum ferritin level in pediatrics with Beta-thalassemia major disease. Iranian J Pediatr Hematol Oncol. 2022; 12(1):34-40. DOI: 10.18502/ijpho.v12i1.8359
39. Miri-Aliabad Gh, Naderi M, Izadi-Nia H. Burkitt leukemia in a child with beta thalassemia major. J Kerman Univ of Med Sci. 2022; 29(1): 91-94. DOI:10.22062/jkmu.2022.91868
40. Zanella S, Garani MC, Borgna-Pignatti C. Malignancies and thalassemia: a review of the literature. Ann N Y Acad Sci. 2016; 1368(1):140-148. PMID: 26916208 DOI: 10.1111/nyas.13005
41. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021; 9(12): e1788. PMID: 34738740 DOI: 10.1002/mgg3.1788
42. Noori T, Ghazisaeedi M, Aliabad GM, Mehdipour Y, Mehraeen E, Conte R, et al. International Comparison of Thalassemia Registries: Challenges and Opportunities. Acta Inform Med. 2019; 27(1):58-63. PMID: 31213746 DOI: 10.5455/aim.2019.27.58-63